CymaBay Therapeutics Inc (NASDAQ:CBAY) – Cantor Fitzgerald issued their FY2019 EPS estimates for CymaBay Therapeutics in a research note issued on Tuesday. Cantor Fitzgerald analyst W. Tanner forecasts that the biopharmaceutical company will post earnings per share of ($0.99) for the year. Cantor Fitzgerald currently has a “Buy” rating and a $16.00 price target on the stock.
CymaBay Therapeutics (NASDAQ:CBAY) last posted its quarterly earnings data on Thursday, March 15th. The biopharmaceutical company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.06. The firm had revenue of $5.20 million for the quarter, compared to analysts’ expectations of $1.25 million.
Shares of CymaBay Therapeutics stock opened at $12.15 on Thursday. CymaBay Therapeutics has a 52-week low of $3.16 and a 52-week high of $15.59. The firm has a market capitalization of $786.85, a price-to-earnings ratio of -14.64 and a beta of 1.96. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.35 and a current ratio of 6.35.
Hedge funds have recently added to or reduced their stakes in the stock. Schwab Charles Investment Management Inc. bought a new stake in shares of CymaBay Therapeutics in the fourth quarter valued at about $115,000. Goldman Sachs Group Inc. bought a new stake in shares of CymaBay Therapeutics in the fourth quarter valued at about $197,000. Virtu Financial LLC raised its holdings in shares of CymaBay Therapeutics by 56.2% in the fourth quarter. Virtu Financial LLC now owns 24,735 shares of the biopharmaceutical company’s stock valued at $228,000 after acquiring an additional 8,899 shares in the last quarter. Sigma Planning Corp raised its holdings in shares of CymaBay Therapeutics by 82.0% in the fourth quarter. Sigma Planning Corp now owns 27,300 shares of the biopharmaceutical company’s stock valued at $251,000 after acquiring an additional 12,300 shares in the last quarter. Finally, Wells Fargo & Company MN raised its holdings in shares of CymaBay Therapeutics by 7,729.2% in the fourth quarter. Wells Fargo & Company MN now owns 39,146 shares of the biopharmaceutical company’s stock valued at $360,000 after acquiring an additional 38,646 shares in the last quarter. Hedge funds and other institutional investors own 61.36% of the company’s stock.
In related news, Director Carl Goldfischer sold 15,000 shares of CymaBay Therapeutics stock in a transaction dated Thursday, March 22nd. The stock was sold at an average price of $13.03, for a total value of $195,450.00. Following the completion of the sale, the director now directly owns 9,340 shares in the company, valued at $121,700.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kurt Von Emster sold 218,057 shares of CymaBay Therapeutics stock in a transaction dated Wednesday, February 14th. The shares were sold at an average price of $15.89, for a total value of $3,464,925.73. The disclosure for this sale can be found here. Insiders sold 819,948 shares of company stock valued at $10,327,654 over the last 90 days. 15.10% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: “CymaBay Therapeutics Inc Forecasted to Earn FY2019 Earnings of ($0.99) Per Share (CBAY)” was first posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://www.tickerreport.com/banking-finance/3294646/cymabay-therapeutics-inc-forecasted-to-earn-fy2019-earnings-of-0-99-per-share-cbay.html.
CymaBay Therapeutics Company Profile
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.